<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITY EXCHANGE ACT OF 1934
Date of report November 7, 2000
----------------------------------------------------------------
NPS PHARMACEUTICALS, INC.
-------------------------------------------------------------------------------
(Exact Name of Registrant as Specified in Its Charter)
Delaware
-------------------------------------------------------------------------------
(State or Other Jurisdiction of Incorporation)
0-23272 87-0439579
----------------------------- ------------------------------------
(Commission File Number) (I.R.S. Employer Identification No.)
420 Chipeta Way, Salt Lake City, Utah 84108-1256
-------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
(801) 583-4939
-------------------------------------------------------------------------------
(Registrant's Telephone Number, Including Area Code)
N/A
-------------------------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
<PAGE>
Item 5. Other Events
On November 7, 2000, NPS Pharmaceuticals, Inc. announced its third-quarter
and nine-month operating results.
The press release is filed as an exhibit to this report and is incorporated
herein by reference.
The press release filed as an exhibit to this report includes "safe harbor"
language, pursuant to the Private Securities Litigation Reform Act of 1995,
indicating that certain statements about NPS's business contained in the press
release are "forward-looking" rather than "historic."
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
NPS PHARMACEUTICALS, INC.
Date: November 7, 2000 /s/ James U. Jensen
----------------------------------
James U. Jensen, Vice President
